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AbstrACt
Introduction Community-acquired pneumonia (CAP) is 
a common indication for antibiotic treatment in young 
children. Data are limited regarding the ideal dose and 
duration of amoxicillin, leading to practice variation 
which may impact on treatment failure and antimicrobial 
resistance (AMR). Community-Acquired Pneumonia: a 
randomIsed controlled Trial (CAP-IT) aims to determine the 
optimal amoxicillin treatment strategies for CAP in young 
children in relation to efficacy and AMR.
Methods and analysis The CAP-IT trial is a multicentre, 
randomised, double-blind, placebo-controlled 2×2 factorial 
non-inferiority trial of amoxicillin dose and duration. 
Children are enrolled in paediatric emergency and 
inpatient environments, and randomised to receive 
amoxicillin 70–90 or 35–50 mg/kg/day for 3 or 7 days 
following hospital discharge. The primary outcome is 
systemic antibacterial treatment for respiratory tract 
infection (including CAP) other than trial medication up to 
4 weeks after randomisation. Secondary outcomes include 
adverse events, severity and duration of parent-reported 
CAP symptoms, adherence and antibiotic resistance. The 
primary analysis will be by intention to treat. Assuming 
a 15% primary outcome event rate, 8% non-inferiority 
margin assessed against an upper one-sided 95% CI, 
90% power and 15% loss to follow-up, 800 children will 
be enrolled to demonstrate non-inferiority for the primary 
outcome for each of duration and dose.
Ethics and dissemination The CAP-IT trial and relevant 
materials were approved by the National Research 
Ethics Service (reference: 16/LO/0831; 30 June 2016). 
The CAP-IT trial results will be published in peer-
reviewed journals, and in a report published by the 
National Institute for Health Research Health Technology 
Assessment programme. Oral and poster presentations 
will be given to national and international conferences, 
and participating families will be notified of the results 
if they so wish. Key messages will be constructed in 
partnership with families, and social media will be used 
in their dissemination.
trial registration number ISRCTN76888927, 
EudraCT2016-000809-36.
IntroduCtIon 
Acute respiratory infections (including 
community-acquired pneumonia; CAP) 
are the most common indication for child-
hood antibiotic use in primary care and 
emergency departments (ED).1–3 Up to 
40% of preschool children attend primary 
strengths and limitations of this study
 ► This well-powered multicentre trial will provide new 
data on efficacy of amoxicillin treatment strategies 
for uncomplicated community-acquired pneumonia 
in young children in developed settings in the post-
pneumococcal vaccine era.
 ► The Community-Acquired Pneumonia: a randomIsed 
controlled Trial (CAP-IT) is one of few randomised 
controlled trials to measure the impact of differ-
ing antibiotic treatment regimens on antimicrobial 
resistance.
 ► The pragmatic approach to eligibility employed by 
the CAP-IT trial is aligned with clinical practice and 
so will facilitate rapid knowledge translation.
 ► Although determining the optimal endpoint for 
pragmatic trials is challenging, use of an Endpoint 
Review Committee in the CAP-IT trial will strengthen 
the confidence in the results.
 ► The generalisability of the CAP-IT trial findings will 
be maximised by the diversity of the enrolled popu-
lation, in both severity and setting.
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care for acute respiratory symptoms, with antibiotics 
prescribed in 30%.3 4 One-third of childhood ED visits 
are for acute respiratory symptoms or fever; up to 15% 
are diagnosed with CAP, with highest antibiotic prescrip-
tion rates in those aged <5 years.5–7 ED attendances and 
hospital admissions for respiratory illness in young chil-
dren increase annually, and two-thirds of antibiotics for 
hospitalised children aged 1–5 years are for CAP.5 8 9 The 
healthcare cost of childhood CAP in England is estimated 
at £8 million/year, though total annual societal costs are 
up to £17 million.10 11 
CAP is a differential diagnosis in any child presenting 
with fever, respiratory symptoms and focal chest signs. 
No gold standard laboratory, microbiological or radio-
logical tests distinguish bacterial from viral infection; 
diagnosis and treatment decisions are based on clinical 
criteria.12–14 Streptococcus pneumoniae is the most commonly 
implicated bacterial pathogen, even in settings with 
routine pneumococcal vaccination (PCV).15–17 Children 
have high rates of bacterial colonisation and carriage of 
resistant organisms which may be transmitted, with partic-
ular risks for vulnerable individuals.18–21 Interventions to 
maintain low antimicrobial resistance (AMR) levels in 
children may therefore have wider benefits.
Amoxicillin is the recommended antibiotic for child-
hood CAP in several international guidelines12 22–24; 
however, there are insufficient data to inform dose, dura-
tion and impact on AMR. The British National Formu-
lary for Children recommends amoxicillin thrice daily 
at 40–80 mg/kg/day. Twice daily dosing is widely recom-
mended due to improved adherence and non-inferiority, 
including by the WHO.22–26 Shorter treatment courses 
are effective in trials performed in low/middle-income 
country settings, though diagnostic and eligibility criteria 
limit generalisability of findings.27 28 Trials from devel-
oped settings predate PCV or include populations with 
high penicillin resistance rates. There are therefore no 
robust data to inform treatment duration, leading to 
variation between 3 and 7 days.23 24 27–30 Assessment of 
treatment efficacy is challenging, as only half of patients 
recover after 10 days, and 90% take up to 4 weeks to 
recover fully.4 31 32 While ongoing ‘minimal’ symptoms 
may trigger retreatment (deemed treatment failure) rela-
tively frequently, the most widely used efficacy measure is 
re-exposure to antibiotics for up to 4 weeks, with recent 
reported rates of 15%.29 31 33
The impact of antibiotics on colonisation with resis-
tant bacteria is complex and dynamic.34–37 Insufficiently 
high dosing could promote selection of resistant patho-
gens, and while the greatest effect on bacterial load is 
achieved early, resistant isolates emerge after 4–5 days.38 39 
Combined effectiveness and resistance data related to 
antibiotic dose and duration would inform antimicrobial 
stewardship and childhood CAP treatment strategies.
The Community-Acquired Pneumonia: a randomIsed 
controlled Trial (CAP-IT) will evaluate efficacy, safety and 
effect on AMR of different durations and doses of oral 
amoxicillin treatment for young children with uncompli-
cated CAP. The specific primary objectives are to deter-
mine whether (1) 3 days is non-inferior to 7 days, and (2) 
35–50 mg/kg/day is non-inferior to 70–90 mg/kg/day.
MEthods
This multicentre, randomised, double-blind, placebo-con-
trolled 2×2 factorial non-inferiority trial aims to enrol 800 
patients over 2 years. Amoxicillin dose and duration are 
assigned simultaneously, resulting in four treatment arms 
(figure 1). This protocol has been written in accordance 
with the Standard Protocol Items: Recommendations for 
Interventional Trials checklist.40
Patient and public involvement
Parents of young children have been involved throughout 
the development and delivery of the CAP-IT trial. In devel-
oping the research question, they advised that shorter 
antibiotic courses would be welcomed if equally effective, 
due to difficulties in giving medicine (due to palatability, 
Figure 1 Possible treatment arms in the CAP-IT trial. CAP-IT, Community-Acquired Pneumonia: a randomIsed controlled Trial. 
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or challenges with day care and daytime doses). For the 
same reasons, parents supported twice daily dosing. A key 
need identified during trial development was support 
for families, including clear symptomatic safety netting, 
close contact and availability of a contact number for the 
local research and clinical teams. Parents reviewed and 
provided input on all information materials to ensure 
they were clear and easy to understand. The CAP-IT Trial 
Steering Committee (TSC) has a parent member, who 
contributes to discussions as the trial progresses, and will 
advise on best methods of disseminating results to fami-
lies as we approach the analysis phase.
trial setting
Sites throughout the UK and Ireland are participating 
from Paediatric Emergency Research in the UK and 
Ireland (PERUKI; www. peruki. org)41 and General and 
Adolescent Paediatric Research in the UK and Ireland 
(GAPRUKI; www. gapruki. org. uk). Participating sites are 
tertiary or secondary hospitals with EDs and inpatient 
areas where potentially eligible children are managed; 
participating centres are listed on the trial website ( www. 
capitstudy. org. uk). Centres are selected based on research 
infrastructure, likely number of recruits, participation 
in feasibility work and proposed training strategies. Site 
principal investigators (PI) are qualified by education, 
training and experience to assume responsibility for 
proper conduct of the trial.
trial population
Participants may be enrolled from EDs, observation units, 
paediatric assessment units (PAU) or inpatient wards, 
provided they fulfil eligibility criteria.
Inclusion criteria
Children are eligible if they are aged ≥6 months, weigh 
6–24 kg, have a clinical diagnosis of CAP (box 1) and will 
be treated with amoxicillin as the sole antibacterial agent 
on hospital discharge. Children must have received none 
or less than 48 hours of treatment with only beta-lactam 
antibiotics at enrolment.
Exclusion criteria
Children are ineligible if they have (1) severe underlying 
chronic disease (including sickle cell anaemia, immuno-
deficiency, chronic lung disease, cystic fibrosis), (2) peni-
cillin allergy or other contraindication to amoxicillin, (3) 
complicated pneumonia (shock, hypotension, altered 
mental state, ventilatory support, empyema, pneumo-
thorax, pulmonary abscess), or (4) bilateral wheezing 
without focal chest signs.
outcome measures
The primary outcome is clinically indicated treatment 
with systemic antibiotic other than trial medication 
for respiratory tract infection (including CAP) up to 
4 weeks after randomisation. Reason and clinical indica-
tion are adjudicated by an Endpoint Review Committee 
(ERC), comprising independent and non-independent 
members. Independent members, including the ERC 
chair, are paediatricians independent of the trial and not 
involved in the clinical care of participants. Non-indepen-
dent members include the chief investigator, project lead 
and trial physician. ERC members review clinical narra-
tive summaries of retreatment primary endpoint events, 
supportive data from patient trial diaries, unscheduled 
visit forms and serious adverse event (SAE) forms; they 
adjudicate whether additional antibiotics were prescribed 
due to CAP (early failure, relapse or recurrence), new 
bacterial infection (respiratory tract infection or other), 
intolerance of trial medication or another reason. Final 
adjudication is based on consensus of the independent 
ERC members.
Secondary outcomes include (1) severity and duration 
of parent-reported CAP symptoms, (2) specified amoxi-
cillin-related adverse events (AE; thrush, skin rashes and 
diarrhoea), (3) phenotypic resistance to penicillin at 
4 weeks in nasopharyngeal (NP) S. pneumoniae isolates, 
and (4) adherence to trial medication.
screening, randomisation, recruitment and consent
The trial flow chart is provided in figure 2. Potential 
participants may require hospital admission for initial 
CAP management or may be discharged immediately 
from an ED or PAU. As antibiotic treatment duration is 
an eligibility criterion, additional eligibility assessment 
procedures are undertaken for those receiving antibiotics 
while in hospital; these differences are outlined in the 
following sections, and in figures 3 and 4.
Screening
Potential participants are identified and screened during 
initial clinical assessment. Participants discharged directly 
from an ED or PAU undergo all trial procedures prior 
to discharge. Children given antibiotics while in hospital 
have a secondary screening episode. Participating centres 
keep anonymised logs of screened children, including 
those who were not approached and those who declined 
participation, which are used to identify any issues for the 
trial, or at a given site.
box 1 definition of clinical diagnosis of CAP
Clinical diagnosis of community-acquired pneumonia (CAP) is defined 
as all of the following:
1. Cough (reported by parents/guardians within 96 hours before 
presentation).
2. Temperature  ≥38°C measured by any method or reported fever 
within 48 hours before presentation. 
3. Signs of laboured/difficult breathing or focal chest signs (one or 
more of the following):
 ► Nasal flaring.
 ► Chest retractions.
 ► Abdominal breathing.
 ► Focal dullness to percussion.
 ► Focal reduced breath sounds.
 ► Crackles with asymmetry.
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Consent
Extensive information is available for recruiting sites, 
including printed and video materials (accessible at 
www. capitstudy. org. uk); all materials have NHS Research 
Ethics Committee (REC) approval. Written informed 
consent is obtained by clinical or research staff from a 
parent/guardian after explanation of the aims, methods, 
benefits and potential hazards of the trial. Families may 
decline participation in all or any aspects of the trial, 
at any time and for any reason, without incurring any 
penalty or affecting treatment. Signed consent forms are 
kept by the site and a copy given to the family. A letter is 
sent to the general practitioner (GP) informing them of 
the trial and the child's involvement.
Enrolment process
At enrolment, recruiting staff review trial materials with 
parents/guardians; these include a symptom diary, partic-
ipant information sheet (PIS), investigational medicinal 
product (IMP) administration instructions and contact 
details for the trial team. The symptom diary collects infor-
mation on clinical and non-clinical elements including 
cough, breathing, temperature, AEs, IMP administration, 
additional antibiotics, any other medication, time off 
work/childcare and other health service use. Relevant 
elements are incorporated into baseline data collected by 
recruiting staff on enrolment clinical report forms. This 
is done with parents/guardians to facilitate their under-
standing of diary content; other baseline data include 
demographics, symptoms, underlying disease, antibiotic 
exposure in the preceding 3 months, chest findings and 
quality of life measures. Participants are registered on 
the online trial database; database access is controlled 
through authorised usernames and passwords and all 
patient identifiable details are confidential.
An NP swab is collected at enrolment. S. pneumoniae 
is identified using culture-based techniques, AMR is 
detected using minimal inhibitory concentration-based 
techniques and respiratory viruses are detected using 
molecular techniques. Stool samples are collected in 
sites participating in ancillary studies, provided specific 
consent is given. There are no other mandatory radiolog-
ical or laboratory tests; if done as part of routine clinical 
Figure 2 CAP-IT trial flow chart. CAP-IT, Community-Acquired Pneumonia: a randomIsed controlled Trial. 
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care, results of haematological, biochemical and chest 
radiograph investigations are recorded.
Randomisation
Participants are allocated 1:1 to each of the two factorial 
randomisations, stratified according to whether or not 
they receive any non-trial antibiotics in hospital before 
being enrolled. A randomisation list is computer gener-
ated based on random permuted blocks by the trial stat-
istician. Based on this list, trial medication (including 
placebo) is labelled and packaged in a blinded manner by 
an independent supplier and delivered to trial sites; treat-
ments are randomly assigned by taking the next sequen-
tially numbered treatment from the relevant supply. As 
it is difficult to taste-match suspensions of amoxicillin 
and placebo, one brand of amoxicillin is used for all 
participants for the first 3 days, followed by a second 
bottle for days 4–7 containing either a second brand 
of amoxicillin or placebo; both form a yellow-coloured 
similar tasting suspension, and parents are instructed to 
expect some change in taste after the first 3 days.
trial treatments
Trial treatment starts on the day of enrolment, with the 
first dose given before discharge where possible. Children 
receive 3 or 7 days of amoxicillin, and suspension is given 
twice daily with dosing by weight band; doses are 35–50 
or 70–90 mg/kg/day. To ensure blinding, amoxicillin 
suspensions of different strengths (125 or 250 mg/5 mL) 
are used so that dose volume is the same regardless of 
treatment arm.
Figure 3 CAP-IT trial schema. CAP-IT, Community-Acquired Pneumonia: a randomIsed controlled Trial; NP, nasopharyngeal. 
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IMP is stored separately from routine medicines, and is 
dispensed in a box containing one bottle of amoxicillin 
and two bottles of either amoxicillin or placebo (blinded 
to contents). Colour labels indicate which should be used 
on days 1–3 and days 4–7. The importance of adherence 
is reinforced when dispensing IMP and during follow-up 
contacts. Adherence is assessed using the symptom diary, 
at telephone follow-up contacts, and at final follow-up 
when families return unused IMP.
IMP may be stopped early for reasons including toxicity, 
clinical change requiring treatment modification, or 
withdrawal of consent. All concomitant medications are 
allowed; if an essential medication interacts with amoxi-
cillin, the IMP is stopped. Although participants are not 
required to give a reason for discontinuing IMP, a reason-
able effort is made to establish this reason.
Situations necessitating unblinding are likely to be rare. 
Severe allergic reactions occur early during amoxicillin 
exposure; immediate discontinuation and trigger avoid-
ance is recommended. Delayed reactions are generally 
mild and resolve with discontinuation. Where retreat-
ment is necessary, unblinding is unlikely to impact on 
antibiotic choice and is therefore unnecessary. If neces-
sary, unblinding is done using an online emergency 
unblinding form.
Follow-up
The trial assessment and follow-up schedule is shown in 
figures 3 and 4. Telephone contact occurs on days 4, 8–10, 
15–17 and 22–24; a face-to-face visit occurs within 2 days 
of day 29. At each contact clinical signs and symptoms 
are reviewed, as are adverse treatment effects, acute 
illnesses requiring medical assessment, new antibiotics 
and IMP adherence. At each face-to-face visit an NP swab 
is collected; if there are any CAP symptoms, examination 
findings and physiological parameters are recorded. If 
a face-to-face visit is not possible for final follow-up, it is 
attempted by telephone. If it is not possible to contact 
families despite reasonable efforts, relevant data are 
sought from the GP if consent has been given to do so.
Additional healthcare contacts may be necessary. 
Parents/guardians liaise with the site trial team if they 
are considering acute clinical assessment during the 
follow-up period, though they are advised to seek imme-
diate emergency assessment if they feel this is required. 
Clinician judgement determines whether investigation, 
treatment or hospitalisation is required. Following any 
unscheduled assessment, symptoms, health service utilisa-
tion and IMP adherence are reviewed by telephone, and 
face-to-face visits arranged if necessary.
Parents/guardians who discontinue IMP are encour-
aged to adhere to the follow-up schedule, and the 
Sponsor is informed. If follow-up is stopped early, data 
already collected are kept for analysis, and the children 
are not replaced in the trial. Samples already obtained are 
processed unless parents/guardians request otherwise.
sample size and power
The sample size is based on demonstrating non-infe-
riority for the primary endpoint for each duration and 
dose. Although inflation factors have been advocated 
for factorial trials to account for interaction between the 
Figure 4 CAP-IT trial assessment schedule (X) indicates tests that may be done if the child's condition requires it or allows 
it, but are not mandatory. *Assessments in this column only undertaken for potential participants receiving inpatient antibiotic 
treatment. †May be done any time before enrolment discussion. ‡Taken before starting antibiotics where possible. CAP-
IT, Community-Acquired Pneumonia: a randomIsed controlled Trial.  
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interventions or a reduction in the number of events, this 
is not necessary if either randomised intervention has a 
null effect (the underlying hypothesis with a non-inferi-
ority design), as marginal analyses can then be conducted. 
Assuming a 15% primary outcome event rate, 8% non-in-
feriority margin assessed against an upper one-sided 95% 
CI, 90% power and 15% loss to follow-up, 800 children 
will be randomised. This is considered a minimum sample 
size; if resources permit, recruitment may continue above 
this number to increase statistical power and precision, 
with the approval of the TSC.
Analysis plan
The primary analysis will be by modified intention to 
treat (ITT), including all participants who take at least 
one IMP dose. The primary endpoint will be analysed 
using time-to-event methods, controlling for previous 
antibiotic exposure. Potential interaction effects between 
dose, duration and previous antibiotic exposure will be 
examined. For some secondary outcomes, including AEs 
and resistance, on-treatment analyses will be performed 
as well as ITT analyses.
The primary analysis of the primary endpoint will 
include only clinically indicated additional systemic 
antibiotic for respiratory tract infection (including 
CAP) as adjudicated by the ERC. Sensitivity analyses 
will be performed to include (1) all systemic antibacte-
rial treatments other than IMP regardless of reason and 
indication (to guard against bias), and (2) only ERC-ad-
judicated clinically indicated systemic antibacterial treat-
ment prescribed specifically for CAP (to provide clinical 
reassurance).
A subgroup analysis will consider CAP severity at presen-
tation, and repeat the main efficacy analysis limited to 
participants with more severe disease. This will provide 
reassurance that an overall null effect (if observed) is not 
due to a dilution effect arising from inclusion of children 
with mild disease of viral aetiology, an important consid-
eration as CAP is diagnosed clinically.
Lower dose and shorter duration will be considered 
‘non-inferior’ to higher dose and longer duration, 
respectively, if the upper limit of the one-sided 95% CI 
for the difference in the proportion of children with 
the primary endpoint at day 29 is less than the non-in-
feriority margin of 8%. However, inference will be based 
primarily on point estimates and CIs rather than binary 
classification of a ‘non-inferior’ or ‘not non-inferior’ 
outcome.42
Ancillary studies
Impact on gastrointestinal microflora
Stool samples will be collected at enrolment and final 
follow-up from 200 children to evaluate the impact of 
amoxicillin exposure on different microbial communi-
ties, including AMR in gastrointestinal commensal flora. 
The baseline sample is collected prior to or as soon as 
possible after starting amoxicillin.
Symptom diary completion methodology
While widespread access to the internet and mobile 
devices suggest web-based questionnaires may be accept-
able and reliable, data supporting this are lacking. As 
it is unclear which is best in terms of completion rates 
we will quasirandomise participants to electronic or 
paper questionnaires based on gender and site. We 
will compare overall data completeness, and complete-
ness of individual items between paper and electronic 
diaries. Data supporting use of one or other approach 
will be important for many trials eliciting primary or key 
secondary parent-reported outcomes through the use of 
symptom diaries.
safety reporting
Definitions for AEs and adverse reactions (AR) of the 
European Union (EU) Directive 2001/20/EC Article 2 
based on the principles of Good Clinical Practice (GCP) 
apply to this trial. The symptom diary prompts for known 
amoxicillin ARs including gastrointestinal symptoms and 
rash; AEs that lead to cessation of trial treatment are 
also reported. When an AE or AR occurs, the PI assesses 
whether this is an SAE using supplied definitions, and the 
level of severity using provided toxicity grading. Where 
an SAE has occurred, an SAE form is completed and 
the Sponsor notified within 24 hours of the PI becoming 
aware. Children are followed up after an SAE until 
complete clinical recovery or until the event has stabi-
lised. Staff follow their institution’s procedure for local 
notification requirements. PIs assess causality of SAEs in 
relation to IMP; assessment of expectedness is completed 
based on common toxicities listed in the Summary of 
Product Characteristics; if a serious AR (SAR) is unex-
pected, the event is classified as a suspected unexpected 
SAR (SUSAR) and reported to the Medicines and Health-
care products Regulatory Agency (MHRA), REC and site 
PIs. Medically qualified staff at the Sponsor and the CI (or 
medically qualified delegate) review all SAE reports. In 
case of disagreement with regard to causality, both opin-
ions are provided in any reports. All SAEs are reported to 
the MHRA and REC in the annual Development Safety 
Update Report.
trial monitoring
Quality assurance and quality control are based on 
a formal risk assessment, to ensure all elements are 
performed in line with applicable regulatory require-
ments. Site initiation visits are done to deliver trial-specific 
training to key clinical and research personnel, which is 
cascaded to all relevant staff; training and delegation logs 
are monitored for completeness. Screening, randomisa-
tion and consent rates are monitored by the trial team at 
the Medical Research Council Clinical Trials Unit (MRC 
CTU) at University College London (UCL), and data are 
checked for consistency, missing data points or possible 
errors, with suspect data returned as queries to ensure 
reliability and validity. PIs allow trial-related monitoring 
including audits, ethics committee review and regulatory 
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inspections, by providing direct access to source data and 
documents as required. The principles of the UK Data 
Protection Act (DPA) are followed.
The Trial Management Group (TMG) comprises the 
CI, clinical and non-clinical investigators, and the CAP-IT 
MRC CTU at UCL team. The TMG is responsible for 
the day-to-day running and management of the trial. 
The TSC has membership from the TMG plus indepen-
dent members, including an independent chair, and 
provides overall guidance and advice. The Independent 
Data Monitoring Committee (IDMC) is the only group 
which sees confidential accumulating data for the trial by 
randomised group. Formal stopping rules are not used 
although the IDMC Charter specifies guidelines for when 
to alert the TSC to consider modifying the trial design. 
These guidelines are conservative to guard against prema-
ture changes to trial design from early inspection of the 
data.
regulatory compliance
This trial is conducted in compliance with GCP princi-
ples as laid down by the Commission Directive 2005/28/
EC, Statutory Instrument 2004 No 1031: Medicines 
for Human Use (Clinical Trials) Regulations 2004 as 
amended, the UK DPA (DPA number: Z5886415) and 
the NHS Research Governance Framework for Health 
and Social Care. Sites inform the Sponsor as soon as they 
are aware of any possible serious breach of compliance, so 
that the Sponsor can report this as per regulatory require-
ments. This is a Clinical Trial of an IMP as defined by 
EU Directive 2001/20/EC. The CTA number is 17141803 
and the EudraCT number is 2016-000809-36.
EthICs And dIssEMInAtIon
The protocol, PIS, consent form and all relevant docu-
mentation were approved centrally by the National 
Research Ethics Service, West London and GTAC REC 
(reference: 16/LO/0831; 30 June 2016). The results 
of the CAP-IT trial will be published in peer-reviewed 
journals read by health professionals managing child-
hood CAP in the UK and internationally, and in a report 
published by the National Institute for Health Research 
Health Technology Assessment programme. To maximise 
impact internationally, oral and poster presentations will 
be given to relevant national and international confer-
ences. Once the trial is completed, all participating fami-
lies will be notified of the results if they wish. The social 
media presence of the organisations involved, including 
PERUKI (@PERUKItweep), will be used to disseminate 
key messages.
dIsCussIon And trIAl stAtus
The first participant was enrolled in February 2017; as 
of 31 January 2019, a total of 690 patients have been 
enrolled from 30 sites. Recruitment is scheduled to finish 
in April 2019, and analysis to be completed by August 
2019. The trial will end after the last follow-up visit of the 
last randomised participant.
Three significant changes to the CAP-IT analysis plan 
have been made during the course of the trial (Protocol 
Version 4.0, 4 December 2018) based on blinded emerging 
trial data. First, although patients were originally intended 
to be stratified based on whether they received inpatient 
antibacterial treatment or were discharged directly from 
hospital, all patients will now be jointly analysed due to 
significant phenotypic overlap. Subgroup efficacy analyses 
will be performed to consider severity of CAP at presen-
tation. Second, the primary endpoint definition has been 
made more specific from ‘all antibiotic prescriptions 
given during follow-up’ to ‘clinically indicated antibiotic 
prescriptions for respiratory tract infections (including 
CAP) as adjudicated by an ERC’. Finally, the non-inferi-
ority margin was adjusted as the primary endpoint event 
rate had been substantially underestimated.
The CAP-IT trial will provide important and robust 
evidence for amoxicillin treatment strategies for child-
hood CAP in developed settings after PCV introduction. 
Its factorial nature will inform amoxicillin dose and dura-
tion, and the optimal regimen for minimal AMR selection. 
Combined with the results of ongoing trials (including 
SAFER43 and SCOUT-CAP [accessible at https:// clinical-
trials. gov/ ct2/ show/ NCT02891915]) in similar health-
care systems, findings from the CAP-IT trial will improve 
and streamline cost-effective care on a global scale.24
The CAP-IT trial provides an important opportunity for 
learning and infrastructure development in acute paedi-
atric trials in the UK and Ireland. Recruiting patients 
to a placebo-controlled randomised trial in EDs, PAUs, 
observation units and inpatient wards has required close 
working across clinical (emergency medicine and general 
paediatric) and research teams, and research networks. 
To date, successful recruitment has been led through 
close communication between the CTU and participating 
sites, with leadership from PERUKI, providing frequent 
opportunities to share best practice in overcoming any 
obstacles to trial delivery. This includes regular contact 
with sites, and a metaplanning exercise prior to the 
second winter of recruitment. Key obstacles identified 
included research training (GCP and study specific), 
out-of-hours recruitment, availability of site research staff 
and delays to discharge caused by study processes. To 
overcome these, a number of new initiatives were devel-
oped, including streamlining of enrolment processes, to 
enable families to have the opportunity to participate in 
this important trial.
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